1 week ago
7
MarketBeat
Mon, March 16, 2026 astatine 10:00 AM CDT 7 min read
-
Revenue and profitability improved: Q4 gross roseate to $35.7M (up 10%) and seven-month modulation gross was $75.5M (up 20%), portion gross borderline climbed to 31% and adjusted EBITDA accrued to $8.6M for the quarter, with nett losses narrowing and year-end liquidity of astir $39M.
-
Cost and cash-flow progress: Management reported six consecutive quarters of declining operating expenses (SG&A down materially) and 4th consecutive 4th of affirmative operating currency flow, with a seven-month modulation escaped currency travel of $3.6M.
-
2026 guidance and lawsuit risks: Lifecore guided to $120–125M revenue, adjusted EBITDA of $20.5–25M, and a nett nonaccomplishment of $28.9–33.4M, portion flagging customer-related variables (supply-chain shifts, inventory timing and delayed launches) that could impact results and noting an expected aseptic request ramp from its largest lawsuit opening successful 2027.
-
Interested successful Lifecore Biomedical, Inc.? Here are 5 stocks we similar better.
Lifecore Biomedical (NASDAQ:LFCR) utilized its fiscal fourth-quarter net telephone to item gross growth, improving margins, and continued outgo reductions during its modulation to a calendar-year reporting cycle. Management besides discussed advancement connected commercialized milestones tied to its largest customer, updates to its improvement and concern improvement pipelines, and provided full-year 2026 fiscal guidance.
For the 4th ended December 31, 2025, Lifecore reported gross of $35.7 million, up 10% from $32.6 million successful the astir comparable prior-year 4th ended November 24, 2024. For the astir seven-month modulation play from May 26, 2025 done December 31, 2025, gross was $75.5 million, up 20% from $63.0 million successful the comparable prior-year period.
→ Amazon Is Rising While the Market Falls—Here’s Why
Chief Financial Officer Ryan Lake attributed the quarterly gross summation chiefly to a $5.6 cardinal summation successful hyaluronic acerb (HA) manufacturing, driven chiefly by the timing of gross tied to the largest customer’s proviso concatenation initiatives. CDMO gross declined $2.4 million successful the quarter, which Lake said reflected the lack of take-or-pay gross successful the comparable play and little aseptic volumes, partially offset by higher improvement gross owed to timing of task enactment for 2 large customers.
On profitability, gross nett successful the 4th was $12.8 million, compared with $11.1 million successful the anterior comparable quarter. Over the seven-month modulation period, gross borderline improved to 31% from 26% a twelvemonth earlier, which Lake said was chiefly driven by higher HA measurement and amended manufacturing absorption.
English (CA) · 
English (US) · 
Spanish (MX) ·